BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36915600)

  • 21. Prognosis analysis of necroptosis-related genes in colorectal cancer based on bioinformatic analysis.
    Liang X; Cheng Z; Chen X; Li J
    Front Genet; 2022; 13():955424. PubMed ID: 36046241
    [No Abstract]   [Full Text] [Related]  

  • 22. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.
    Zheng H; Liu H; Ge Y; Wang X
    Cancer Cell Int; 2021 Oct; 21(1):552. PubMed ID: 34670584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.
    Sun K; Huang C; Li JZ; Luo ZX
    World J Surg Oncol; 2022 Oct; 20(1):342. PubMed ID: 36253777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
    Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
    Front Oncol; 2021; 11():674897. PubMed ID: 34367961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.
    Li X; Wen D; Li X; Yao C; Chong W; Chen H
    Front Immunol; 2020; 11():1678. PubMed ID: 33013820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
    Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
    Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune infiltration and a necroptosis-related gene signature for predicting the prognosis of patients with cervical cancer.
    Xing X; Tian Y; Jin X
    Front Genet; 2022; 13():1061107. PubMed ID: 36685937
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
    Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
    Front Genet; 2022; 13():1001239. PubMed ID: 36425071
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
    Yang Z; Zi Q; Xu K; Wang C; Chi Q
    Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma.
    Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal N; Kota V; Rojiani MV; Rojiani AM; Kolhe R
    Sci Rep; 2021 Apr; 11(1):7561. PubMed ID: 33828127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Ferroptosis-Related Gene Signature Identified as a Novel Prognostic Biomarker for Colon Cancer.
    Qi X; Wang R; Lin Y; Yan D; Zuo J; Chen J; Shen B
    Front Genet; 2021; 12():692426. PubMed ID: 34276794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of fatty acid metabolism-related genes in colorectal cancer and their potential implications for immunotherapy.
    Huang X; Sun Y; Song J; Huang Y; Shi H; Qian A; Cao Y; Zhou Y; Wang Q
    Front Immunol; 2023; 14():1301452. PubMed ID: 38045683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
    Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
    Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic roles of a novel basement membranes-related gene signature in lung adenocarcinoma.
    Zhu X; Liu X; Qiu X; Niu Z; Dong W; Song Y
    Front Genet; 2023; 14():1100560. PubMed ID: 36845403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.